360 related articles for article (PubMed ID: 12421676)
21. Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness.
Weiss TW; Arnesen H; Seljeflot I
Metabolism; 2013 Jul; 62(7):1008-13. PubMed ID: 23428306
[TBL] [Abstract][Full Text] [Related]
22. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus.
Aoki Y; Narazaki M; Kishimoto T; Tosato G
Blood; 2001 Nov; 98(10):3042-9. PubMed ID: 11698289
[TBL] [Abstract][Full Text] [Related]
23. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier.
Linker RA; Lühder F; Kallen KJ; Lee DH; Engelhardt B; Rose-John S; Gold R
J Neuroimmunol; 2008 Dec; 205(1-2):64-72. PubMed ID: 18950871
[TBL] [Abstract][Full Text] [Related]
24. Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130.
Yasukawa K; Futatsugi K; Saito T; Yawata H; Narazaki M; Suzuki H; Taga T; Kishimoto T
Immunol Lett; 1992 Feb; 31(2):123-30. PubMed ID: 1740350
[TBL] [Abstract][Full Text] [Related]
25. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
26. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
[TBL] [Abstract][Full Text] [Related]
27. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
28. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex.
Ringheim GE; Szczepanik AM; Petko W; Burgher KL; Zhu SZ; Chao CC
Brain Res Mol Brain Res; 1998 Mar; 55(1):35-44. PubMed ID: 9645958
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
31. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.
Pignatti P; Ciapponi L; Galle P; Hansen MB; Massa M; Meazza C; Paonessa G; Novick D; Ciliberto G; Martini A; De Benedetti F
Clin Exp Immunol; 2003 Feb; 131(2):355-63. PubMed ID: 12562400
[TBL] [Abstract][Full Text] [Related]
32. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex.
Jones SA; Rose-John S
Biochim Biophys Acta; 2002 Nov; 1592(3):251-63. PubMed ID: 12421670
[TBL] [Abstract][Full Text] [Related]
33. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice.
Peters M; Schirmacher P; Goldschmitt J; Odenthal M; Peschel C; Fattori E; Ciliberto G; Dienes HP; Meyer zum Büschenfelde KH; Rose-John S
J Exp Med; 1997 Feb; 185(4):755-66. PubMed ID: 9034153
[TBL] [Abstract][Full Text] [Related]
34. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
35. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
36. [Soluble IL-6 receptors].
Jabłońska E
Postepy Hig Med Dosw; 1998; 52(2):133-8. PubMed ID: 9640977
[TBL] [Abstract][Full Text] [Related]
37. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation.
Pflanz S; Kurth I; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 2000 Dec; 165(12):7042-9. PubMed ID: 11120832
[TBL] [Abstract][Full Text] [Related]
38. Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease.
Ikeda K; Kinoshita M; Tagaya N; Shiojima T; Taga T; Yasukawa K; Suzuki H; Okano A
Brain Res; 1996 Jul; 726(1-2):91-7. PubMed ID: 8836549
[TBL] [Abstract][Full Text] [Related]
39. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
40. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
